Cell Pathways and Glaxo to conduct trial

CLPA and Glaxo (GLX; LSE:GLXO) will conduct a U.S. Phase I/II safety and efficacy study in elderly patients with advanced non-small cell lung cancer with the combination of CLPA's Aptosyn exisulind an...